ValiRx (VAL.L) Stock Price

ValiRx Price

LSE·CLOSED
0.00
​
Market closed

Revenue at ValiRx has contracted by 1.6% per year over the past 18 years to 31,372.00 GBP. For ValiRx, the net margin of -7,115.1% is down versus -3,609.1% a few years ago.

ValiRx stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ValiRx business model & stock analysis

ValiRx PLC is a British biotech company founded in 1997. It is headquartered in London. The company focuses on the development of drugs for the treatment of cancer and other serious diseases. ValiRx has a portfolio of several different products at various stages of development. The products range from preclinical to clinical studies. The company has four main divisions: I. VAL401 - A drug for the treatment of lung cancer. VAL401 is the company's leading product. It is an orally administered drug intended for the treatment of non-small cell lung cancer. The drug is currently in Phase IIb clinical trials. II. VAL201 - A drug for the treatment of prostate cancer. VAL201 is an orally administered drug intended for the treatment of prostate cancer. The drug is in Phase IIb clinical trials. III. VAL101 - A drug for the treatment of endometriosis. VAL101 is ValiRx's most advanced product in preclinical development. It is a drug for the treatment of endometriosis. IV. VAL301 - A drug for the treatment of ovarian cancer. VAL301 is a drug for the treatment of ovarian cancer. It is currently in preclinical development. ValiRx's products are based on a technology platform called Gene Inactivation by Chromatin Engineering (GENIE). The technology uses RNA interference to selectively destroy cancer cells without attacking healthy tissue. The company collaborates with various research institutions and universities to bring innovative ideas into the product pipeline. ValiRx is a publicly traded company listed on the London Stock Exchange. Overall, ValiRx has a promising portfolio of products at various stages of development. The focus is on developing drugs that can improve the lives of cancer patients.

Frequently asked questions about ValiRx

The business model of ValiRx PLC is focused on the development and commercialization of novel therapeutics for the treatment of cancer. The company's approach involves identifying and validating drug targets, conducting preclinical and clinical trials, and seeking partnerships for the distribution and commercialization of its products. ValiRx PLC leverages its expertise in drug discovery and development to create innovative therapies that have the potential to improve patient outcomes and advance cancer treatment options. Through strategic collaborations and ongoing research, ValiRx PLC aims to bring its products to market and address the unmet medical needs in the field of oncology.

ValiRx PLC is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of ValiRx PLC in the market include pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis.

ValiRx PLC is a pharmaceutical company focused on developing innovative therapeutics and diagnostics for the treatment and detection of cancer. With a history spanning over two decades, ValiRx has successfully advanced its research programs and built a diverse pipeline of potential drug candidates. The company is committed to addressing unmet medical needs and improving patient outcomes through its proprietary technologies and strategic collaborations. ValiRx PLC aims to revolutionize cancer treatment by delivering targeted therapies and personalized medicine solutions. As a leading player in the biotech industry, ValiRx PLC remains dedicated to making significant contributions to the field of oncology.

ValiRx PLC has achieved several significant milestones. The company successfully completed Phase 1 trials for VAL201, its lead compound used in the treatment of prostate cancer and other advanced solid tumors. ValiRx also entered into research collaborations with leading academic institutions and pharmaceutical companies, which further validated its innovative technologies and drug pipeline. Additionally, the company achieved positive clinical results for VAL301, a novel treatment for endometriosis. ValiRx PLC successfully raised funds through share placements and partnerships, enabling the continuation of its research and development efforts. These achievements demonstrate ValiRx PLC's commitment to advancing healthcare through the development of effective and innovative therapeutics.

ValiRx PLC is primarily present in the United Kingdom.

ValiRx PLC represents a set of core values and a corporate philosophy that guide its operations. The company focuses on innovation, scientific rigor, and a commitment to improving patient outcomes. ValiRx PLC emphasizes the importance of integrity, transparency, and ethical behavior in all aspects of its business. The company strives to develop novel therapeutic solutions, leveraging its expertise in drug development and precision medicine. ValiRx PLC aims to enhance shareholder value through strategic partnerships, efficient project management, and a strong focus on commercialization opportunities. With a dedication to addressing unmet medical needs, ValiRx PLC aims to deliver innovative healthcare solutions for the benefit of patients worldwide.

9 analysts currently rate the ValiRx stock: 8 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the ValiRx share trades at 0.00 EUR (0.00 GBP).

The ValiRx share (VAL.L) is listed on 3 stock exchanges, including: London (VAL.L), Frankfurt (EAJF.F).

ValiRx PLC is a biopharmaceutical company focused on researching, developing, and marketing drugs for the treatment of cancer and other diseases. The company was founded in 1997 and is headquartered in London, UK. ValiRx's business model consists of three main divisions: research and development, clinical trials, and marketing and distribution. ValiRx's research and development department focuses on exploring new compounds that have the potential to treat cancer as well as other diseases such as Alzheimer's and Parkinson's. The company believes that combination therapy is a promising approach to cancer treatment and therefore possesses several patented technologies for combining drug compounds. The clinical trials division of ValiRx is also an integral part of the business model. The company is currently conducting several clinical trials to evaluate the efficacy and safety of its drugs. These studies are carried out in collaboration with leading academic institutions and aim to expedite the regulatory approval of the drugs. ValiRx also has an extensive pipeline of drugs in various stages of development. The company has already launched several products, including VAL201 and VAL401. VAL201 is currently being studied in clinical trials for the treatment of prostate cancer, while VAL401 is used for nerve-related gastrointestinal disorders. The company also pursues an aggressive growth strategy through acquisitions and partnerships. In 2019, ValiRx announced its intention to acquire US biotech firm Plato Biosciences for $2.2 million. Plato Biosciences has developed a novel bacteriophage-based technology that can be used to treat antibiotic-resistant infections. Overall, ValiRx has a promising business model with a strong focus on research and development and clinical trials. The company has an extensive pipeline of promising drugs and is well-positioned to continue growing and solidifying its position as a leading player in cancer research.

The revenue cannot currently be calculated for ValiRx.

The profit cannot currently be calculated for ValiRx.

The P/E ratio cannot be calculated for ValiRx at the moment.

The P/S cannot be calculated for ValiRx currently.

The Eulerpool Quality Score for ValiRx is 2/10.

The ISIN of ValiRx is GB00BLH13C52. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ValiRx is A2P1SH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ValiRx is VAL.L. The ticker symbol is used to trade ValiRx shares on the stock exchange.

Fair ValueTerminal
0.00 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
2,852.00 GBP
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website valirx.com
Currency
GBP
Initial public offering
Feb 28, 2000
ISIN
GB00BLH13C52
Cusip
G9313Z140
Sedol
BLH13C5
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
0.32
P/B Ratio
0.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-78.15 %
Last updated Nov 16, 2026, 3:49 AM

ValiRx Ticker

FRANKFURT · EAJF.FLONDON · VAL.LLONDON STOCK EXCHANGE · VAL.L

ValiRx FIGI

VAL:LN · BBG000BD7297VAL1:XL · BBG000HD8254VAL1:XT · BBG000HD9985VAL1:XW · BBG000HD99W8VAL1:EU · BBG000HD9CT5VALL:PO · BBG002JV34V0VAL1:XV · BBG00591BBH1VALL:B3 · BBG006T78Q21VALL:L3 · BBG006TBBHQ2EAJF:GR · BBG009H372Y6EAJF:GF · BBG009H372Z5EAJF:GS · BBG009H37329

All fundamentals and in-depth analysis of ValiRx

Our stock analysis for ValiRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ValiRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.